511 related articles for article (PubMed ID: 32966993)
1. Neoadjuvant Chemotherapy in Pancreatic Cancer: An Appraisal of the Current High-Level Evidence.
Müller PC; Frey MC; Ruzza CM; Nickel F; Jost C; Gwerder C; Hackert T; Z'graggen K; Kessler U
Pharmacology; 2021; 106(3-4):143-153. PubMed ID: 32966993
[TBL] [Abstract][Full Text] [Related]
2. Intraoperative Radiation Therapy (IORT) for Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma (BR/LA PDAC) in the Era of Modern Neoadjuvant Treatment: Short-Term and Long-Term Outcomes.
Harrison JM; Wo JY; Ferrone CR; Horick NK; Keane FK; Qadan M; Lillemoe KD; Hong TS; Clark JW; Blaszkowsky LS; Allen JN; Castillo CF
Ann Surg Oncol; 2020 May; 27(5):1400-1406. PubMed ID: 31758284
[TBL] [Abstract][Full Text] [Related]
3. Network meta-analysis comparing neoadjuvant chemoradiation, neoadjuvant chemotherapy and upfront surgery in patients with resectable, borderline resectable, and locally advanced pancreatic ductal adenocarcinoma.
Hu Q; Wang D; Chen Y; Li X; Cao P; Cao D
Radiat Oncol; 2019 Jul; 14(1):120. PubMed ID: 31291998
[TBL] [Abstract][Full Text] [Related]
4. Opinions and use of neoadjuvant therapy for resectable, borderline resectable, and locally advanced pancreatic cancer: international survey and case-vignette study.
Heinrich S; Besselink M; Moehler M; van Laethem JL; Ducreux M; Grimminger P; Mittler J; Lang H; Lutz MP; Lesurtel M;
BMC Cancer; 2019 Jul; 19(1):675. PubMed ID: 31288786
[TBL] [Abstract][Full Text] [Related]
5. Neoadjuvant and adjuvant chemotherapy in pancreatic cancer.
Klaiber U; Leonhardt CS; Strobel O; Tjaden C; Hackert T; Neoptolemos JP
Langenbecks Arch Surg; 2018 Dec; 403(8):917-932. PubMed ID: 30397779
[TBL] [Abstract][Full Text] [Related]
6. Neoadjuvant Treatment in Pancreatic Cancer.
Oba A; Ho F; Bao QR; Al-Musawi MH; Schulick RD; Del Chiaro M
Front Oncol; 2020; 10():245. PubMed ID: 32185128
[TBL] [Abstract][Full Text] [Related]
7. Clinical benefits of neoadjuvant chemoradiotherapy for adenocarcinoma of the pancreatic head: an observational study using inverse probability of treatment weighting.
Fujii T; Satoi S; Yamada S; Murotani K; Yanagimoto H; Takami H; Yamamoto T; Kanda M; Yamaki S; Hirooka S; Kon M; Kodera Y
J Gastroenterol; 2017 Jan; 52(1):81-93. PubMed ID: 27169844
[TBL] [Abstract][Full Text] [Related]
8. Neoadjuvant and Adjuvant Treatments for Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma: The Current Status of Pancreatic Ductal Adenocarcinoma Treatment in Japan.
Ei S; Takahashi S; Ogasawara T; Mashiko T; Masuoka Y; Nakagohri T
Gut Liver; 2023 Sep; 17(5):698-710. PubMed ID: 36843421
[TBL] [Abstract][Full Text] [Related]
9. FDG-PET Predicts Neoadjuvant Therapy Response and Survival in Borderline Resectable/Locally Advanced Pancreatic Adenocarcinoma.
Abdelrahman AM; Goenka AH; Alva-Ruiz R; Yonkus JA; Leiting JL; Graham RP; Merrell KW; Thiels CA; Hallemeier CL; Warner SG; Haddock MG; Grotz TE; Tran NH; Smoot RL; Ma WW; Cleary SP; McWilliams RR; Nagorney DM; Halfdanarson TR; Kendrick ML; Truty MJ
J Natl Compr Canc Netw; 2022 Sep; 20(9):1023-1032.e3. PubMed ID: 36075389
[TBL] [Abstract][Full Text] [Related]
10. Treatment of Locally Advanced Pancreatic Ductal Adenocarcinoma.
Loehrer AP; Ferrone CR
Dig Surg; 2016; 33(4):343-50. PubMed ID: 27216011
[TBL] [Abstract][Full Text] [Related]
11. Neoadjuvant multimodal treatment of pancreatic ductal adenocarcinoma.
Silvestris N; Longo V; Cellini F; Reni M; Bittoni A; Cataldo I; Partelli S; Falconi M; Scarpa A; Brunetti O; Lorusso V; Santini D; Morganti A; Valentini V; Cascinu S
Crit Rev Oncol Hematol; 2016 Feb; 98():309-24. PubMed ID: 26653573
[TBL] [Abstract][Full Text] [Related]
12. Impact of Neoadjuvant Therapy in Resected Pancreatic Ductal Adenocarcinoma of the Pancreatic Body or Tail on Surgical and Oncological Outcome: A Propensity-Score Matched Multicenter Study.
Lof S; Korrel M; van Hilst J; Alseidi A; Balzano G; Boggi U; Butturini G; Casadei R; Dokmak S; Edwin B; Falconi M; Keck T; Malleo G; de Pastena M; Tomazic A; Wilmink H; Zerbi A; Besselink MG; Abu Hilal M;
Ann Surg Oncol; 2020 Jun; 27(6):1986-1996. PubMed ID: 31848815
[TBL] [Abstract][Full Text] [Related]
13. A Phase II Clinical Trial of Molecular Profiled Neoadjuvant Therapy for Localized Pancreatic Ductal Adenocarcinoma.
Tsai S; Christians KK; George B; Ritch PS; Dua K; Khan A; Mackinnon AC; Tolat P; Ahmad SA; Hall WA; Erickson BA; Evans DB
Ann Surg; 2018 Oct; 268(4):610-619. PubMed ID: 30080723
[TBL] [Abstract][Full Text] [Related]
14. Intention to treat outcomes among patients with pancreatic cancer treated using International Study Group on Pancreatic Surgery recommended pathways for resectable and borderline resectable disease.
Kamarajah SK; Chatzizacharias N; Hodson J; Marcon F; Kalisvaart M; Punia P; Ting Ma Y; Dasari B; Marudanayagam R; Sutcliffe RP; Muiesan P; Mirza DF; Isaac J; Roberts KJ
ANZ J Surg; 2021 Jul; 91(7-8):1549-1557. PubMed ID: 33576568
[TBL] [Abstract][Full Text] [Related]
15. Clinical challenges associated with utility of neoadjuvant treatment in patients with pancreatic ductal adenocarcinoma.
Gray S; de Liguori Carino N; Radhakrishna G; Lamarca A; Hubner RA; Valle JW; McNamara MG
Eur J Surg Oncol; 2022 Jun; 48(6):1198-1208. PubMed ID: 35264307
[TBL] [Abstract][Full Text] [Related]
16. Upfront Surgery and Surgery Following Neoadjuvant Treatment of Pancreatic Ductal Adenocarcinoma: A Comparative Analysis of Short-term Postoperative Outcomes.
Jung JH; Yoon SK; Yoon SJ; Shin SH; Han IW; Heo JS
Anticancer Res; 2021 Nov; 41(11):5703-5712. PubMed ID: 34732443
[TBL] [Abstract][Full Text] [Related]
17. Optimal management of patients with operable pancreatic head cancer: A Markov decision analysis.
Rieser CJ; Narayanan S; Bahary N; Bartlett DL; Lee KK; Paniccia A; Smith K; Zureikat AH
J Surg Oncol; 2021 Oct; 124(5):801-809. PubMed ID: 34231222
[TBL] [Abstract][Full Text] [Related]
18. Postoperative complications after resection of borderline resectable and locally advanced pancreatic cancer: The impact of neoadjuvant chemotherapy with conventional radiation or stereotactic body radiation therapy.
Blair AB; Rosati LM; Rezaee N; Gemenetzis G; Zheng L; Hruban RH; Cameron JL; Weiss MJ; Wolfgang CL; Herman JM; He J
Surgery; 2018 May; 163(5):1090-1096. PubMed ID: 29395234
[TBL] [Abstract][Full Text] [Related]
19. Neoadjuvant therapy offers longer survival than upfront surgery for poorly differentiated and higher stage pancreatic cancer.
Nurmi A; Mustonen H; Parviainen H; Peltola K; Haglund C; Seppänen H
Acta Oncol; 2018 Jun; 57(6):799-806. PubMed ID: 29241394
[TBL] [Abstract][Full Text] [Related]
20. Predictors of Resectability and Survival in Patients With Borderline and Locally Advanced Pancreatic Cancer who Underwent Neoadjuvant Treatment With FOLFIRINOX.
Michelakos T; Pergolini I; Castillo CF; Honselmann KC; Cai L; Deshpande V; Wo JY; Ryan DP; Allen JN; Blaszkowsky LS; Clark JW; Murphy JE; Nipp RD; Parikh A; Qadan M; Warshaw AL; Hong TS; Lillemoe KD; Ferrone CR
Ann Surg; 2019 Apr; 269(4):733-740. PubMed ID: 29227344
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
